MindMed Ready To Take LSD Therapy Into Phase III For Anxiety
Treatment Infrastructure In Place Due To J&J’s Spravato
Executive Summary
Mind Medicine’s LSD product MM120 will move into Phase III in the second half of 2024 after it showed efficacy in generalized anxiety disorder out to 12 weeks with a single administration in Phase IIb.